Description: Microbiotix, Inc. seeks a highly motivated part-time Ph.D. Pharmacologist. The successful candidate will represent the PK/PD/ADME discipline on discovery and development anti-infective project teams. Experience with experimental design, implementation and data interpretation, as well as strategies and tactics to advance high-quality small molecules is essential. PK/PD/ADME experience with anti-bacterial and anti-viral small molecules would be desirable, but not mandatory. As part of a multidisciplinary team, and as an interface with CROs, organization and communication skills will be paramount. The candidate should have a strong understanding of DMPK and PK/PD areas applicable to animal models and translation into humans and will lead the DMPK function for discovery projects from early target validation stages, into the nomination of the development candidate, and through support of clinical studies. Duties will include planning and directing studies; gathering, analyzing, interpreting and disseminating DMPK and PK/PD data; and standardizing drug doses. Candidates are expected to have industry experience with both in vitro ADME and small animal in vivo assessments (tolerability, PK, PK/PD modelling and simple efficacy studies). Candidate should be familiar with standard analytical methods (HPLC, LC-MS) and basic DMPK modelling (WinNonLin, etc.). Microbiotix, Inc. is an equal opportunity employer, and offers competitive compensation and benefits. This is a one-year part-time, potentially renewable, contract position. This position could be a combination of telecommuting and in office, as personal needs or location dictates.
Qualifications: • Ph.D or Pharm.D in Pharmacology/Toxicology or Biological Sciences Experience: • 5+ years (industrial preferred)
Internal Number: Pharma1
About Microbiotix Inc
Microbiotix, Inc. is a biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases. Microbiotix has active projects in the antibacterial, antiviral, and antiparasitic areas, including many diseases that are underserved by the pharmaceutical industry, and we collaborate extensively with academic investigators to solve complex problems in these areas.
The Company's lead therapeutic compound, MBX-400, a novel agent for the treatment of human cytomegalovirus, is currently in Phase IB clinical testing. MBX-400 is a non-natural nucleoside analog that has shown improved activity against resistant strains and less toxicity than existing HCMV therapies.
BACK TO TOP
ASPET Career Center is Just One of the Benefits.
Discover what else ASPET has to offer!
The job you are trying to reach from was originally posted at ASPET Career Center.